On 5th April 2024, over 60 researchers braved the train strikes and gusty weather to gather at Lady Margaret Hall in Oxford and engage in a day full of scientific talks, posters and discussions on the topic of adaptive immune receptor (AIR) analysis!
Lots of work has been put into making AMD designed GPUs to work nicely with GPU accelerated frameworks like PyTorch. Despite this, getting performant code on non-NVIDIA graphics cards can be challenging for both users and developers. Even in the case where the developer has appropriately optimised for each platform there are often gaps in performance where, at the driver-level, instructions to the GPU may not be optimised fully. This is because software developed using CUDA can benefit from optimisations like operation-fusing without having to specify in many cases.
This may not be much of a concern for most researchers as we simply use what is available to us. Most of the time this is usually NVIDIA GPUs and there is hardly a choice to it. NVIDIA is aware of this and prices their products accordingly. Part of the problem is that system designers just dont have an incentive to build AMD platfroms other than for highly specialised machines.
This blogpost is a short notice about recent quality-of-life and feature updates to our Therapeutic Structural Antibody Database (Thera-SAbDab). We hope these changes will make the database more user-friendly and facilitate new analyses…
OPIG’s growing immunoinformatics team continues to develop and openly distribute a wide variety of databases and software packages for antibody/nanobody/T-cell receptor analysis. Below is a summary of all the latest updates (follows on from v1.0 and v2.0).
16:30 BST 27/06/2023 Oxford, UK. A large number of scientists were spotting riding bicycles across town, to the consternation of onlookers. The event was the Oxford Protein Informatics Group (OPIG) “tour de farce” 2023. A circular bike ride from the Department of Statistics, to The Up in Arms (Marston), The Trout Inn (Godstow), The Perch (Port Meadow) and The Holly Bush (Osney Island). This spurred great bystander-anxiety due to one of a multitude of factors: the impressive size of the jovial horde, the erraticism of the cycling, the deplorable maintenance of certain bikes, and the unchained bizarrerie of the overheard dialogue.
For several years now, we have distributed the SAbDab database and SAbPred tools as a virtual machine, SAbBox, via Oxford University Innovation. This virtual machine allows a user to utilise the tools and database locally, allowing for high-throughput analysis and keeping confidential data within a local network. Initially distributed under a commercial licence, the platform proved popular and, in 2020, we introduced a free academic licence to enable our academic colleagues to use our tools and database locally.
Following requests from users, in 2021 we released a new version of the platform packaged as a Singularity container. This included all of the features of SAbBox, allowing Linux users to take advantage of the near bare-metal performance of Singularity when running SAbPred tools. Over the past year, we have made lots of improvements to both SAbBox platforms, and have more work planned for the coming year. I’ll briefly outline these developments below.
pMHCs are set to become a major target class in drug discovery; unusual peptide fragments presented by MHC can be used to distinguish infected/cancerous cells from healthy cells more precisely than over-expressed biomarkers. In this blog post, I will highlight a prototype resource: Dr. Chris Thorpe’s new database of pMHC structures, histo.fyi.
histo.fyi provides a one-stop shop for data on (currently) around 1400 pMHC complexes. Similar to our dedicated databases for antibody/nanobody structures (SAbDab) and T-cell receptor (TCR) structures (STCRDab), histo.fyi will scrape the PDB on a weekly basis for any new pMHC data and process these structures in a way that facilitates their analysis.
When I started my PhD in late 2018, AI hadn’t really entered the field of de novo protein design yet – at least not in a big way. Rosetta’s approach of continually ranking new side chain rotamers on a fixed backbone was still the gold standard for the ‘structure-to-sequence’ problem. And of course before long we had AI making waves in the structure prediction field, eventually culminating in the AlphaFold2 we all know and love.
Now, towards the end of my PhD, we are seeing the emergence of new generative models that learn from existing pdb structures to produce sequences that will (or at least should) fold into viable, sensible and crucially natural-looking shapes. ProtGPT2 is a good example (https://www.nature.com/articles/s41467-022-32007-7), but there are several more. How long before these models start reliably generating not only shapes but functions too? Jury’s out, but it’s looking more and more feasible. Safe to say the field as a whole has evolved massively during my time as a graduate student.
Last year, the Structural Antibody Database (SAbDab) listed a record-breaking 894 new antibody structures, driven in no small part by the continued efforts of the researchers to understand SARS-CoV-2.
Fig. 1: The aggregate growth in antibody structure data (all methods) over time. Taken from http://opig.stats.ox.ac.uk/webapps/newsabdab/sabdab/stats/ on 25th May 2022.
In this blog post I wanted to highlight the major driving force behind this curve – the huge increase in cryo electron microscopy (cryoEM) data – and the implications of this for the field of structure-based antibody informatics.
